Gastric Cancer | Tumor

Opdivo Combined with Yervoy or Chemo Improves Survival in Unresectable and Advanced Esophageal Cancer

June 5th 2021, 3:00pm


Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

FDA Approves Opdivo for Adjuvant Treatment of Esophageal and Gastroesophageal Junction Cancer

May 20th 2021, 6:17pm


Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this occurred.

FDA Approves Keytruda for Use With Trastuzumab and Chemotherapy for Subtypes of Stomach Cancer

May 5th 2021, 6:58pm


Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.

FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer

April 16th 2021, 4:57pm


The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.

Opdivo with Chemotherapy Treatment Under Priority Review by FDA Shows Promise for Patients with Advanced Gastrointestinal Cancers

March 21st 2021, 3:00pm


In clinical trials, Opdivo in combination with chemotherapy improved overall survival and progression-free survival compared to chemotherapy alone.

‘I Knew Something Was Wrong Before the Doctors Did’

February 10th 2021, 7:00pm


Theresa Germano sat down with HEAL® to discuss her journey with cancer, how her daughter became her hero and how listening to her body benefited her in the end.

Bavencio Shows No Improvement of Overall Survival for Patients with Gastric Cancers

January 21st 2021, 2:00pm


For patients with gastric/ gastroesophageal cancer, treatment with Bavencio after chemotherapy shows favorable safety, but no overall survival improvement.

FDA Grants Priority Review for Opdivo for Several Gastrointestinal Cancers

January 20th 2021, 4:00pm


The priority review will focus on Opdivo with chemotherapy for the treatment several gastrointestinal cancers, which has recently become a rising area in novel treatment development.

Alleviating Pandemic-Related Anxiety Over Returning to the Clinic for Clinical Trials

January 16th 2021, 2:00pm


In an interview with CURE®, expert Martha Raymond explains the importance of clinical trials during the COVID-19 pandemic and how clinicians must find a way to help ease patients anxieties as they return to the clinic.

Enhertu Receives FDA Approval for Gastroesophageal, Gastric Cancer Subset

January 15th 2021, 9:44pm


The Food and Drug Administration approved Enhertu to treat adults with locally advanced or metastatic HER2-positive gastroesophageal or gastric cancer who have previously received a trastuzumab-based treatment regimen.